Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07024277
Starting soon Phase 2

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

NCT07024277 · tracked via the Priya Life Science China tracker
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase
Phase 2
Started
2025-08
Last updated
2025-06-17

Condition(s) studied

Neuroendocrine Prostate Cancer

Investigational drug(s) / intervention(s)

ZG006 →

ZG006: ZG006 will be administered as an intravenous (IV) infusion.

Study summary

This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.

Eligibility

Sex
MALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Male Participants aged 18 to 80 years (inclusive); * Advanced metastatic neuroendocrine prostate cancer; * disease progression after at least one line of platinum-based systemic therapy or intolerance to toxicity; * Measurable disease according to RECIST v1.1 criteria; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Exclusion Criteria: * Known positive test for human immunodeficiency virus (HIV) or hepatitis； * Patients were deemed unsuitable for participating in the study by the investigator for any reason.

Primary outcome measure(s)

  • Modified Best Overall Response（mBOR） — Baseline to 12 months
    mBOR will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications.

Trial sites (1)

FacilityCityRegionStatus
Fudan university shanghai cancer center Shanghai Shanghai Municipality

More Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials in China

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer Recruiting
Study of ZGGS34 in Participants With Advanced Solid Tumors Recruiting
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular Starting soon
ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma Starting soon
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07024277 on ClinicalTrials.gov ↗ ← All trials in China